Local intracerebral immunomodulation using interleukin-expressing mesenchymal stem cells in glioblastoma.

CONCLUSION: Local MSC-based immunomodulation is able to efficiently alter the immunosuppressive microenvironment in glioblastoma. The long-lasting therapeutic effects warrant a rapid clinical translation of this concept and have led to planning of a phase I/II study of apceth-301 in recurrent glioblastoma.
PMID: 31988196 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 26, 2020 Category: Cancer & Oncology Authors: Mohme M, Maire CL, Geumann U, Schliffke S, Dührsen L, Fita KD, Akyüz N, Binder M, Westphal M, Guenther C, Lamszus K, Hermann FG, Schmidt NO Tags: Clin Cancer Res Source Type: research